1. Tullmann DF, Haugh KH, Dracup KA, Bourguignon C. A randomized controlled trial to reduce delay in older adults seeking help for symptoms of acute myocardial infarction. Res Nurs Health. 2007;30(5):485-97. [
DOI:10.1002/nur.20245] [
PMID]
2. Prabhakaran D, Jeemon P, Sharma M, et al. The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018;6(12):e1339-e51.
3. Piegas LS, Avezum A, Pereira JC, et al. Risk factors for myocardial infarction in Brazil. Am Heart J. 2003;146(2):331-8. [
DOI:10.1016/S0002-8703(03)00181-9]
4. Kannel WB. Contribution of the framingham study to preventive cardiology. J Am College Cardiol. 1990;15(1):206-11. [
DOI:10.1016/0735-1097(90)90203-2]
5. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol. 2008;51(2):210-47. [
DOI:10.1016/j.jacc.2007.10.001] [
PMID]
6. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (London, England). 1999;354(9180):716-22. [
DOI:10.1016/S0140-6736(99)07403-6]
7. Howland RD, Mycek MJ, Harvey RA, Champe PC. Lippincott's illustrated reviews: Pharmacology: Lippincott Williams & Wilkins Philadelphia; 2006.
8. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-425.
9. Aasa M, Henriksson M, Dellborg M, et al. Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-results of the Swedish early decision reperfusion study (SWEDES) trial. Am Heart J. 2010;160(2):322-8. [
DOI:10.1016/j.ahj.2010.05.008] [
PMID]
10. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (London, England). 2001;358(9282):605-13. [
DOI:10.1016/S0140-6736(01)05775-0]
11. Ng S, Lim T, Tan S, Yap R, Tay E. Comparison of efficacy and safety of streptokinase and tenecteplase in patients with ST-segment elevated acute myocardial infarction (STEMI) in Melaka Hospital. Proceedings of the 9th National Pharmacy R&D Conference; 2016.
12. Tourani S, Bashzar S, Nikfar S, Ravaghi H, Sadeghi M. Effectiveness of tenecteplase versus streptokinase in treatment of acute myocardial infarction: a meta-analysis. Tehran Univ Med J. 2018;76(6):380-7.
13. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Europ Heart J. 1985;6(7):556-85. [
DOI:10.1093/oxfordjournals.eurheartj.a061905] [
PMID]
14. Trialists FT. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343(8893):311-22. [
DOI:10.1016/S0140-6736(94)91161-4]
15. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA. 2001;286(4):442-9. [
DOI:10.1001/jama.286.4.442] [
PMID]
16. Wilcox RG. Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data. Am J Cardiol. 1996;78(12):20-3. [
DOI:10.1016/S0002-9149(96)00739-4]
17. Walley T, Dundar Y, Hill R, Dickson R. Superiority and equivalence in thrombolytic drugs: an interpretation. QJM. 2003;96(2):155-60. [
DOI:10.1093/qjmed/hcg020] [
PMID]
18. Investigators G. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Eng J Med. 1993;329(10):673-82. [
DOI:10.1056/NEJM199309023291001] [
PMID]
19. Taylor GJ, Moses HW, Koester D, et al. A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study). Am J Cardiol. 1993;72(14):1010-4. [
DOI:10.1016/0002-9149(93)90854-6]
20. Cherng WJ, Chiang CW, Kuo CT, Lee CP, Lee YS. A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction. Am Heart J. 1992;123(4):841-6. [
DOI:10.1016/0002-8703(92)90685-O]
21. Verstraete M, Bory M, Collen D, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet. 1985;325(8433):842-7. [
DOI:10.1016/S0140-6736(85)92208-1]
22. Della GIPLS, Miocardico SNI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet (London, England). 1986;1:397.
23. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Sleight R. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-60. [
DOI:10.1016/S0140-6736(88)92833-4]
24. Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ. 1991;303(6816):1499-503. [
DOI:10.1136/bmj.303.6816.1499] [
PMID] [
PMCID]
25. Collins R, Peto R, Flather M, et al. ISIS-4-A randomised factorial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58.050 patient with suspected acute myocardial-infarction. Lancet. 1995;345(8951):669-85. [
DOI:10.1016/S0140-6736(95)90865-X]
26. Collins R, Peto R, Parish S, Sleight P. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. Am J Cardiol. 1993;71(12). [
DOI:10.1016/0002-9149(93)90591-Y]
27. White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. New England Journal of Medicine. 1989;320(13):817-21. [
DOI:10.1056/NEJM198903303201301] [
PMID]
28. Liang F, Hu D, Shi X, Gao M, Wei J, Zhao H, et al. Efficacy and safety of single-bolus tenecteplase compared with front-loaded alteplase in Chinese patients with acute myocardial infarction. J GeriatrCardiol. 2007;4(3):137-41.
29. Van de Werf F, Barron H, Armstrong P, Granger C, Berioli S, Barbash G, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. A comparison of TNK-tPA and rt-PA. European heart journal. 2001;22(24):2253-61. [
DOI:10.1053/euhj.2001.2686] [
PMID]
30. Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, et al. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. American heart journal. 2003;146(1):27-32. [
DOI:10.1016/S0002-8703(03)00117-0]
31. Binbrek AS, Rao NS, Neimane D, Hatou E, Abdulali S, Sobel BE. Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction. The American journal of cardiology. 2004;93(12):1465-8. [
DOI:10.1016/j.amjcard.2004.03.004] [
PMID]
32. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation. 1998;98(25):2805-14. [
DOI:10.1161/01.CIR.98.25.2805] [
PMID]
33. Jeong MH, Kim W, Kang JC, et al. A comparison of tenecteplase (TNK-tPA) and alteplase (rt-PA) in korean patients with acute myocardial infarction (a randomized, multi-centered coronary angiographic trial). Korean Circ J. 2003;33(5):362-73. [
DOI:10.4070/kcj.2003.33.5.362]
34. Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015;36(10):605-14. [
DOI:10.1093/eurheartj/ehu218] [
PMID] [
PMCID]
35. Mehta SR, Eikelboom JW, Yusuf S. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet. 2000;356(9228):449-54. [
DOI:10.1016/S0140-6736(00)02552-6]
36. Jinatongthai P, Kongwatcharapong J, Foo CY, et al. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. Lancet. 2017;390(10096):747-59. [
DOI:10.1016/S0140-6736(17)31441-1]
37. Thelengana A, Radhakrishnan DM, Prasad M, Kumar A, Prasad K. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis. ActaneurolBelgica. 2019;119(3):359-67. [
DOI:10.1007/s13760-018-0933-9] [
PMID]
38. Kheiri B, Osman M, Abdalla A, et al. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J ThrombThrombol. 2018;46(4):440-50. [
DOI:10.1007/s11239-018-1721-3] [
PMID]
39. Nepal G, Kharel G, Ahamad ST, Basnet B. Tenecteplase versus alteplase for the management of acute ischemic stroke in a low-income country-Nepal: Cost, Efficacy, and Safety. Cureus. 2018;10(2):e2178. [
DOI:10.7759/cureus.2178]
40. Mohseni J, Kazemi T, Maleki MH, Beydokhti H. A Systematic review on the prevalence of acute myocardial infarction in Iran. Heart Views. 2017;18(4):125-32. [
DOI:10.4103/HEARTVIEWS.HEARTVIEWS_71_17] [
PMID] [
PMCID]